Simplify Logo

Full-Time

Director/Senior Director of Market Access

Policy Development

Updated on 9/6/2024

BillionToOne

BillionToOne

201-500 employees

Molecular diagnostics for prenatal and oncology testing

Hardware
Social Impact
Biotechnology
Healthcare

Compensation Overview

$200k - $250kAnnually

+ Equity Options + Industry Leading Benefits

Mid, Senior

Remote in USA

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Required Skills
Communications
Public Policy
Requirements
  • An advanced degree (GC along with PhD or MD) in a relevant scientific or health discipline.
  • Proven experience in the full lifecycle development of MolDX Local Coverage Determinations (LCDs).
  • 3 to 5 years of experience as a Medical Science Liaison or in a similar role within oncology.
  • 3 to 5 years of experience in developing local coverage determinations and medical policies for emerging technologies.
  • Expertise in articulating scientific insights in discussions with health insurance companies, Laboratory Benefit Managers, and other technical assessment bodies.
  • A track record of establishing and nurturing relationships with key stakeholders within health plans, including Medical Directors and policy teams.
  • Documented relationships and collaboration with NCCN on clinical guidelines.
Responsibilities
  • Demonstrate a deep understanding of reimbursement, healthcare policy, CMS, and MolDX processes to inform policy development.
  • Spearhead the creation of medical policies for Northstar Select™, Northstar Response™, and forthcoming oncology products.
  • Collaborate with Directors of Market Access to design and execute strategies that secure coverage and payment for innovative technologies.
  • Implement proactive and comprehensive strategies focused on CMS and MolDX to optimize reimbursement.
  • Partner with the Revenue Cycle Management (RCM) team to ensure that BillionToOne capitalizes on revenue opportunities while maintaining alignment with reimbursement guidelines.
  • Continuously monitor CMS and HHS agency activities that may impact BillionToOne’s public policy landscape.
  • Analyze existing and emerging payer policies, market trends, pricing strategies, and barriers to provider and patient access.
  • Engage cross-functionally with commercial, medical affairs, communications, patient advocacy, and other Corporate Affairs teams to drive business objectives.
  • Collect and synthesize stakeholder feedback for interaction with health technology assessment agencies, NCCN, payers, and patient associations.
  • Maintain an informed perspective on the translational medicine, oncology, companion diagnostics, and pharmaceutical services markets, including competitive dynamics and payer challenges.

BillionToOne specializes in molecular diagnostics within the healthcare sector, focusing on prenatal screening and oncology testing. Their proprietary QCT technology allows for the detection and quantification of diseases at a single base-pair level, enabling the identification of minute variations in DNA. The company offers two main products: Northstar Select™, which helps determine the best initial therapy for patients, and Northstar Response™, which tracks the effectiveness of that therapy. Unlike many competitors, BillionToOne's business model centers on providing these diagnostic services directly to healthcare providers, generating revenue through the sale of their testing services. The goal of BillionToOne is to enhance the accuracy, efficiency, and accessibility of molecular testing, driven by a commitment to growth, equality, and teamwork in making a positive impact on healthcare.

Company Stage

Series C

Total Funding

$295.9M

Headquarters

Menlo Park, California

Founded

2016

Growth & Insights
Headcount

6 month growth

7%

1 year growth

20%

2 year growth

76%
Simplify Jobs

Simplify's Take

What believers are saying

  • The recent $130M Series D funding round, led by PremjiInvest, positions BillionToOne for significant growth and expansion.
  • Partnerships with major companies like Johnson & Johnson enhance their credibility and market reach.
  • The appointment of Ross Taylor as CFO brings seasoned financial leadership, supporting the company's hypergrowth trajectory.

What critics are saying

  • The competitive landscape in molecular diagnostics is intense, requiring continuous innovation to maintain a leading position.
  • Dependence on healthcare providers for revenue could be impacted by changes in healthcare policies or economic downturns.

What makes BillionToOne unique

  • BillionToOne's QCT technology offers single base-pair resolution, providing unparalleled accuracy in molecular diagnostics.
  • Their focus on both prenatal screening and oncology testing allows them to address critical healthcare needs with specialized products like Northstar Select™ and Northstar Response™.
  • The company's mission-driven culture and commitment to accessibility set them apart in the biotech industry.

Benefits

Competitive pay

Retirement savings package

Parental leave

Free snacks & lunches

Medical, dental, & vision premiums

On campus perks

Free-on-site EV charging